These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32800099)

  • 1. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
    Duffy SW; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith RA; Evans A; Blyuss O; Johns L; Ellis IO; Myles J; Sasieni PD; Moss SM
    Lancet Oncol; 2020 Sep; 21(9):1165-1172. PubMed ID: 32800099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
    Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
    Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.
    Moss SM; Wale C; Smith R; Evans A; Cuckle H; Duffy SW
    Lancet Oncol; 2015 Sep; 16(9):1123-1132. PubMed ID: 26206144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tailored Breast Screening Trial (TBST)].
    Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
    Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.
    Moss SM; Cuckle H; Evans A; Johns L; Waller M; Bobrow L;
    Lancet; 2006 Dec; 368(9552):2053-60. PubMed ID: 17161727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
    Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
    Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
    FH01 collaborative teams
    Lancet Oncol; 2010 Dec; 11(12):1127-34. PubMed ID: 21093374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
    Allgood PC; Maroni R; Hudson S; Offman J; Turnbull AE; Peacock L; Steel J; Kirby G; Ingram CE; Somers J; Fuller C; Threlfall AG; Gabe R; Maxwell AJ; Patnick J; Duffy SW
    Lancet Oncol; 2017 Jul; 18(7):972-980. PubMed ID: 28522311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
    Duffy SW; Mackay J; Thomas S; Anderson E; Chen TH; Ellis I; Evans G; Fielder H; Fox R; Gui G; Macmillan D; Moss S; Rogers C; Sibbering M; Wallis M; Warren R; Watson E; Whynes D; Allgood P; Caunt J
    Health Technol Assess; 2013 Mar; 17(11):vii-xiv, 1-95. PubMed ID: 23489892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of mammography screening: updated overview of the Swedish randomised trials.
    Nyström L; Andersson I; Bjurstam N; Frisell J; Nordenskjöld B; Rutqvist LE
    Lancet; 2002 Mar; 359(9310):909-19. PubMed ID: 11918907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Singh N; Ryan A; Karpinskyj C; Carlino G; Taylor J; Massingham SK; Raikou M; Kalsi JK; Woolas R; Manchanda R; Arora R; Casey L; Dawnay A; Dobbs S; Leeson S; Mould T; Seif MW; Sharma A; Williamson K; Liu Y; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Jacobs IJ; Parmar M
    Lancet; 2021 Jun; 397(10290):2182-2193. PubMed ID: 33991479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial.
    Wooldrage K; Robbins EC; Duffy SW; Cross AJ
    Lancet Gastroenterol Hepatol; 2024 Sep; 9(9):811-824. PubMed ID: 39038482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Gothenburg Breast Screening Trial.
    Bjurstam N; Björneld L; Warwick J; Sala E; Duffy SW; Nyström L; Walker N; Cahlin E; Eriksson O; Hafström LO; Lingaas H; Mattsson J; Persson S; Rudenstam CM; Salander H; Säve-Söderbergh J; Wahlin T
    Cancer; 2003 May; 97(10):2387-96. PubMed ID: 12733136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Adjunctive Ultrasonography for Breast Cancer Detection Among Women Aged 40-49 Years With Varying Breast Density Undergoing Screening Mammography: A Secondary Analysis of a Randomized Clinical Trial.
    Harada-Shoji N; Suzuki A; Ishida T; Zheng YF; Narikawa-Shiono Y; Sato-Tadano A; Ohta R; Ohuchi N
    JAMA Netw Open; 2021 Aug; 4(8):e2121505. PubMed ID: 34406400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
    Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality.
    Tabár L; Vitak B; Chen HH; Yen MF; Duffy SW; Smith RA
    Cancer; 2001 May; 91(9):1724-31. PubMed ID: 11335897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years.
    Moss S; Thomas I; Evans A; Thomas B; Johns L;
    Br J Cancer; 2005 Mar; 92(5):949-54. PubMed ID: 15726102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.